Positive allosteric modulators (PAMs) that target the M<sub>1</sub> muscarinic acetylcholine (ACh) receptor (M<sub>1</sub> mAChR) are potential treatments for cognitive deficits in conditions such as Alzheimer disease and schizophrenia.
Subtype-selective allosteric modulation of the M<sub>1</sub> muscarinic acetylcholine (ACh) receptor (M<sub>1</sub> mAChR) is an attractive approach for the treatment of numerous disorders, including cognitive deficits.